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Survey of Fertility Preservation Options
Available to Patients With Cancer Around
the Globe
abstract
Purpose Oncofertility focuses on providing fertility and endocrine-sparing options to patients who undergo
life-preserving but gonadotoxic cancer treatment. The resources needed to meet patient demand often are
fragmented along disciplinary lines. We quantify assets and gaps in oncofertility care on a global scale.
Methods Survey-based questionnaires were provided to 191 members of the Oncofertility Consortium
Global Partners Network, a National Institutes of Health–funded organization. Responseswere analyzed to
measure trends and regional subtleties about patient oncofertility experiences and to analyze barriers to
care at sites that provide oncofertility services.
Results Sixty-three responses were received (response rate, 25%), and 40 were analyzed from oncofertility
centers in 28 countries. Thirty of 40 survey results (75%) showed that formal referral processes and psy-
chological care are provided to patients at the majority of sites. Fourteen of 23 respondents (61%) stated that
some fertility preservation services are not offered because of cultural and legal barriers. The growth of
oncofertility and its capacity to improve the lives of cancer survivors around the globe relies on concentrated
efforts to increase awareness, promote collaboration, share best practices, and advocate for research funding.
Conclusion This survey reveals global and regional successes and challenges and provides insight into
what is needed to advance the field andmake the discussion of fertility preservation andendocrinehealth a
standard component of the cancer treatment plan. As the field of oncofertility continues to develop around
the globe, regular assessment of both international and regional barriers to quality care must continue to
guide process improvements.
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INTRODUCTION
Theprimary goal of oncofertility is to increase access
for patients with cancer to fertility counseling and
fertility preservation options to improve the overall
quality of life of cancer survivors.1,2 As the field of
oncofertility expands, a need exists to clarify the
oncofertility services that are provided on a global
scaleand todefine thechallenges facedbyproviders
and patients. Current barriers represent areas for
improvement in this growing field and can be
addressed through collaboration with professional
societies and governments. For these reasons, we
conducted a global oncofertility resource assess-
ment survey to document the experiences of exist-
ing oncofertility centers within the Oncofertility
Consortium (OC) Global Partners Network.
METHODS
Survey Design
A survey was sent to members of the OC Global
Partners Network and international experts in the
field to collect information about the fertility pres-
ervation services offered to patients with cancer
and the barriers to oncofertility care at their cen-
ters. The survey was written in English because all
potential participants were English speaking. In-
vited studyparticipantswere clinicians, researchers,
nurses, patient navigators, and psychologists. A pilot
survey was generated for attendees of the 2015
Oncofertility Conference and after cognitive debrief-
ing, was subsequently converted to an electronic
format through the use of SurveyMonkey software.
The final versionwas e-mailed to 191contacts of the
OC Global Partners Network. The Northwestern
University institutional review board determined that
the study did not constitute research that involves
human subjects; therefore, additional institutional
review board review and approval was not required.
Survey Inclusion/Exclusion
Upon receipt of multiple responses from the same
center, scores were averaged to generate mean
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values. All open-ended response data provided by
the study participants are reported in the results.
Surveys were excluded from the analysis if re-
spondents did not provide contact or identifica-
tion information, if the survey was left blank, or if
duplicate responses were submitted. Appendix
Table A1 lists the countries and organizations that
participated in the study.
Survey Questions
Respondents were asked a total of 12 questions
about organization of referrals, patient access to
medical professionals, barriers and challenges
faced at centers, and estimated reimbursement
of oncologic fertility preservation by governmental
entities or insurance companies (Appendix Table
A2). Six questions were dichotomous (yes/no),
with space provided for open-ended comments
(questions 1, 2, 3, 6, 10, and 11). Three questions
were multiple choice, where only one answer
could be selected (questions 7, 8, and 9). Two
questions were multiple response where respon-
dents could select oneormoreanswers (questions
5 and 12). One question contained a matrix of
drop-down menus where respondents could se-
lect whether a fertility preservation service is of-
fered to specific age ranges of female and male
patients (question 4).
Analysis of Survey Results
Survey responseswereexported toMicrosoft Excel
software (Microsoft Corporation, Redmond, WA).
The dichotomous and multiple response ques-
tions were coded with numerical values (yes = 1,
no = 2) to facilitate statistical analysis. Graphs
were generated with both SPSS for Windows
version 23.0 (IBMCorporation, Armonk, NY) and
Microsoft Excel software. Descriptive statistics
were used to analyze the quantitative data.
Two individuals who were blinded to the region
analyzed written responses.
RESULTS
A total of 63 responses were received (response
rate, 25%), and of those, 47 were valid, which
resulted in the inclusion of 40 centers after
combining multiple responses from the same
center. Appendix Table A1 lists the participat-
ing centers by country and continent. Appendix
Table A3 lists the frequencies and percentages
of responses to dichotomous (yes/no) ques-
tions. The denominator for each survey question
changed according to the number of responses
because not all respondents opted to answer each
question.
Organization of Referrals
In terms of organizational structure, 30 of 40 re-
spondents (75%) reported having an established
referral system at their site, and 35 of 40 (88%)
reported having a patient registry. The largest
group of respondents, 14 of 37 (38%), indicated
that the average length of time at their center
between cancer diagnosis and fertility preserva-
tion consultation is 1 to 2 days. Nine of 37 re-
spondents (24%) reported that the time between
consultation and fertility preservation procedures
was 1 to 2 days; nine of 37 (24%) also reported the
time to be 3 to 5 days between consultation and
fertility preservation procedures. Eleven of 36
(31%) indicated the time between fertility preser-
vation and cancer treatment was 3 to 5 days.
(Appendix Table A4).
Respondents reported a variety of referral pro-
cesses. Some centers see patients with cancer
for fertility preservation counseling within 24
hours of diagnosis, such as at the IVF Centro
de Reproduccio´n in Panama and at the Seoul
National University Bundang Hospital in South
Korea; two sites specified that the referral from
cancer diagnosis to fertility consultation can
take > 3 weeks.
As indicated in the open-ended survey responses,
oncologists refer their patients at the majority of
centers (16 of 19). However, at the Centro de
Preservaç~ao da Fertilidade in Portugal, Hunting-
ton Medicina Reprodutiva in Brazil, and McGill
University Health Centre Reproductive Centre in
Canada, patients may set up their own appoint-
ments. The Seoul National University Bundang
Hospital attributed referral challenges to discrep-
ancies between the policies that govern oncolo-
gists and reproductive physicians. At the Royal
Children’s Hospital in Melbourne, Australia, the
development of written informational support, clear
referral pathways, and fertility preservation man-
agement protocols within the pediatric setting have
doubled the rate of fertility counseling since 2013.
The Clinic of Endocrinological Gynecology at the
Jagiellonian University Medical College in Poland
noted time burden and a lack of awareness among
clinicians as its two greatest barriers to care.
Patient Access to Specialized Professionals
Nine of 34 respondents (26%) reported having a
nurse navigator, social worker, or specific onco-
fertility patient navigator for patients with cancer of
reproductive age. At the Ceara´ Blood Center in
Fortaleza, Brazil, an oncology nurse navigator (a
registerednursewithoncology-specificknowledge)
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offers individualizedassistance topatients and their
families. This patient navigator provides the edu-
cation and resources necessary to expedite stress-
ful decision making for the patient and ensures
timely access to quality health and psychosocial
care.
With regard to patient counseling, 30 of 40 re-
spondents (75%) provide routine psychological
support to patients. At the Centre for Fertility
Preservation at the Coimbra Hospital and Univer-
sity Centre in Portugal, a psychologist specializes
in helping patients through fertility preservation
decision making after a cancer diagnosis. If the
patient ultimately decides toundergoaprocedure,
the psychologist provides support throughout the
entirety of the fertility preservation process by
gauging the patient’s mental condition and emo-
tional state.
ServicesOfferedat the Initial Fertility Preservation
Consultation
Thirty seven of 40 survey respondents (93%)
identified the services offered to patients at their
facilities. For pediatric males and females, the
services most commonly offered are testicular
tissue cryopreservation (n=16) and ovarian tissue
cryopreservation (n = 26), respectively. For ado-
lescent males and females, sperm cryopreserva-
tion (n=34)andeggcryopreservation (n=26) and
ovarian tissue cryopreservation (n = 28) are avail-
able options. In the adult age category,more third-
party options were discussed with both males and
females, including adoption (n = 29) and donation
of eggs (n = 23), sperm (n = 25), and embryos (n =
28). Of the 40 respondents, only one stated that
gestational surrogacy is mentioned as a future
possible consideration to pediatric females; six
reported mentioning gestational surrogacy to ad-
olescent females, and 18 reportedmentioning the
option to adult females (Fig 1).
Barriers and Challenges
The majority of respondents, 37 of 40 (93%),
identified barriers to care (Table 1). Fourteen of
23 respondents (61%) identified religious or cul-
tural restrictions to oncofertility careofferedat their
sites. However, lack of insurance coverage and
significant financial burden to patients were iden-
tified most often (both 62%; 23 of 37).
In addition, 9 of 37 respondents (24%) indicated
a lack of providers as a challenge their center
faces. In Brazil, physicians’ resistance to discuss
fertility issues may be one of the greatest chal-
lenges, above even the high estimated costs
noted (Table 2).
Eleven of 37 respondents (30%) stated that the
costs of fertility preservation procedures are cov-
ered by insurance or national or provincial health
systems, whereas 26 of 37 respondents, more
than two thirds (70%), reported that costs are
not covered (Appendix Table A3). The highest
costs of oncofertility care were noted in Japan.
InGifu, oncofertilityprocedurecostswere reported
to beashighas5,000USdollars (USD)per patient
for ovarian tissue cryopreservation, with sperm
cryopreservation costing only approximately 150
USD and egg and embryo cryopreservation cost-
ing from 2,500 to 3,500 USD per patient. Re-
spondents from St Mariana University in Kawasaki
reported even higher costs for oncofertility proce-
dures, which range from 6,000 to 8,000 USD. In
contrast, at the Radboud University Medical Center
in the Netherlands, all fertility preservation op-
tions are reimbursed by insurance or the hospital
(Table 2).
The survey responses indicated various legal
challenges about specific procedures. One no-
table cultural and legal barrier to oncofertility care
was related to the use of surrogacy. This topic is
explored in the accompanying article.4
DISCUSSION
In this study,we foundglobal trends in the services
offered to pediatric, adolescent, and young adult
patients with cancer, including some notable re-
gional differences, and learned more about chal-
lengesandbarriers tocare. The informationgathered
in this analysis would be stronger with a higher
response rate and a field-wide study population.
The OC Global Partners Network was recently
founded in 2013, so the survey respondentswere
limited to the currentmembers of the group at the
timeof this study. This cohort of professionalswas
selected because of their declared commitment
to the field of oncofertility and ease of contact.
However, it is important to recognize that those
surveyed are considered leaders in oncofertility
care, and as a result, the findings may highlight
the most successful settings. An online survey
and the existenceof languagebarriers couldhave
contributed to the relatively low response rate,
although the response rate is comparable to other
clinical surveys.5
An oncofertility consult ideally occurs in the short
window of time between a cancer diagnosis and
the start of treatment. A major goal of the field is
for this conversation to become routine practice
in cancer treatment.6 Timely referral of a patient
with a new diagnosis by an oncologist to a re-
productive endocrinologist is vital and requires an
3 jgo.org JGO – Journal of Global Oncology
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effective connection between the two medical
specialists. Studies show that fewer than one
half of reproductive-age patients who undergo
cancer treatment are referred to endocrinol-
ogy specialists despite recommendations from
ASCO;7 this is due to a combination of factors,
including a lack of knowledge among oncolo-
gists, a hesitance of patients to bring up their
desire to preserve their fertility, and the inability to
delay treatment of aggressive cancers.8 As a re-
sult of these obstacles, patient navigators9 and
established referral processes are critical to en-
sure patients receive the best and most efficient
fertility preservation care possible. The current
results are consistent with this observed discon-
nect, with only one quarter of survey respondents
reporting the use of specialized oncofertility
navigators.
In addition, national registries are ideal for
collecting population data, which can be
useful for evaluating the success of fertility
preservation referrals. The majority of cen-
ters included in this study confirmed that
they have established oncofertility registries.
In 2015, the Fertility Understanding Through
Registry and Evaluation (FUTURE) research
group launched the first Web- and population-
based national oncofertility registry in Austra-
lia and New Zealand.10 These databases track
patient-specific information, including demo-
graphic details, cancer stage, and fertility-
related issues as a result of cancer or its treat-
ment.11 FUTURE is expected to be a leading
model for other countries to highlight their own
systems’ assets as well as to identify their unmet
needs.
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Fig 1. Fertility
preservation services
offered to patients at survey
respondent organizations.
(A) Pediatric patients. (B)
Adolescent patients. (C)
Adult patients.
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Table 2. Regional Estimates of the Potential Out-of-Pocket Financial Burden of Fertility Preservation Procedures for Patients With Cancer
Continent and Country Coverage of Fertility Preservation Procedures Rank of Cost to Patient
Africa
Egypt No coverage. Some centers at university hospitals may offer lower-cost
services, andcharities support patientswith fewer resources. In general, the
cost of a single cycle of IVF/ICSI is between 500 and 1,000 USD.
$$
Tunisia Insurance coverage applies only for couples with demonstrated infertility.
Patients must pay for gonadotropins, which often are expensive. Costs for
procedures are low and vary from 80 to 135 USD depending on the
procedure.
$-$$$
Asia
China Patients pay out-of-pocket, but the cost tends to be approximately 270 USD. $$
India Fertility preservation procedures are not covered by insurance. Patients must
pay themselves. Tissue storage costs are, in some cases, covered by in-
house funding or grants.
$$$$
Iran (Islamic Republic of) Partial insurance coverage for ART procedures. Only counseling and
preliminary tests are typically covered. However, operations and other
fertility preservation techniques often are thoroughly covered by insurance,
such as ovarian transposition, ovarian transplantation, and laparoscopic
surgery for ovarian tissue retrieval, especially in government hospitals.
However, larger insurance companies provide various treatment insurance
so that patients may afford hospital expenses and even pay no money in
many cases where infertility is a factor, but ART treatment is still an
exception to this.
$$-$$$
Japan Patients pay out-of-pocket (including for consultations) because insurance
does not cover cryopreservation procedures, which can cost from 150 to
8,000 USD. Some municipal or prefectural governments just started
financial reimbursement for fertility preservation treatment, but this is still
not common.
$-$$$$
Korea (Republic of) No insurance coverage. Patients must pay all costs for fertility preservation
treatment themselves. The cost is approximately 2,000 to 3,000 USD for
oocyteor embryocryopreservation.Forovarian tissuecryopreservation, only
operation costs may be partially covered by insurance. In the end, the total
costs for ovarian tissue cryopreservation are similar to oocyte or embryo
cryopreservation.
$$$-$$$$
Turkey No insurance coverage. $$$$
Europe
Austria Reimbursement differs from province to province. Generally, storage is not
covered, which in Innsbruck amounts to 310 USD per year. Ovarian tissue
cryopreservation is sometimes reimbursed by insurance, but this differs
among insurance companies. Cryopreservation of oocytes and
spermatozoa are not covered and must be entirely funded by patients. IVF
for thegenerationof blastocytesmaybepaid forby the IVFFund if thecouple
has an indication (pathospermia, endometriosis, tubal factor, or PCO), but
this is handled differently depending on the institution.
$$
Belgium Fertility preservation procedures are free to patients younger than 18 years
because techniques are still considered experimental for minors. Patients
withcancerolder than18yearspaya reducedprice (comparedwithpatients
without cancer) of approximately 560USDout-of-pocket v several thousand
USD. Embryo cryopreservation is fully reimbursed in all cases. TheMinister
of Healthcare announced in 2016 that partial reimbursement of fertility
preservation procedures for patients with cancer would begin in 2017.
0-$$
Denmark Insurance covers the cost of ovarian tissue cryopreservation. 0
France French social security covers all costs (whatever the technique used) for
patients with a medical indication for fertility preservation. Fertility
preservation without medical indication is not authorized.
0
Germany Insurance partially covers costs. $$
(Continued on following page)
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Table 2. Regional Estimates of the Potential Out-of-Pocket Financial Burden of Fertility Preservation Procedures for Patients With Cancer (Continued)
Continent and Country Coverage of Fertility Preservation Procedures Rank of Cost to Patient
Poland No coverage. Cost to the patient is approximately 670 to 2,780 USD for all
cryopreservation procedures. Consultation and medical examinations are
reimbursed under the Polish National Health Service, but ART and
cryopreservation procedures, such as transplantation, are not covered. The
cost of themedical consultation for a patient interested in fertility-preserving
methods is reimbursed on the basis of their health insurance.
$$$-$$$$
Portugal Consultations, medical examinations, technical procedures, and
cryopreservation procedures are all covered under the PortugueseNational
Health Service. Medication is covered at 69%, so patients must pay for the
other 31% (cost to the patient for medication is approximately several
hundred USD).
0-$$
Netherlands Most costs are reimbursed by insurance, but experimental procedures, such
ascryopreservationof ovarian tissueor testicular stemcells, is paid forby the
hospital.
0
Russian Federation Nocoverage.The first 12months of tissue storagecosts are approximately 220
USD. For the second year on, costs are approximately 100 USD per year.
Discounts are offered for long-term storage. Adolescents younger than 25
years are covered by charities.
0-$$$
Spain Public insurance covers cryopreservation of eggs, sperm, and embryos aswell
as a limited number of cycles of assisted reproduction. Because ovarian
cortex and immature testicular tissue cryopreservation are considered
experimental procedures, they are covered by research grants.
0
United Kingdom of Great Britain and
Northern Ireland
State coverage for most options (although some restrictions on access exist)
and partial research funding for experimental options (ovary and testis
cryopreservation) are available.
0
North America
Canada Varies greatly by province. In Quebec, fees for IVF procedures,
cryopreservation, and medication are all covered by the government
insurance plan, including storage fees. In other provinces, IVF is not
government funded, but someprovinces offer a tax credit, and not-for-profit
foundations offer some funding. As of December 21, 2015, the Ontario
government also started an Ontario Fertility Program, which covers egg and
sperm freezing for oncologic/medical need. However, in all other provinces
in Canada, no provincial health coverage of fertility preservation procedures
exists.
0-$
Mexico No insurance coverage. Tissue collection costs are covered by the hospital.
Some IVF laboratoriescharge for tissuestorage,whereasothersmaynot. IVF
laboratories determine costs on an individual basis. Costs to the patient are
generally high.
$$$$
Panama Costs are partially reimbursed by a private national foundation for fertility
patients.Medications are reimbursed by pharmacotherapeutic companies.
Patients must pay a small fee.
$$
United States Insurancemay cover some of the costs of fertility preservation procedures, but
copays are usually significant. Public assistance does not cover any costs.
$$
Oceania
Australia Insurance will cover some costs toward day procedures, anesthesia, and egg
and embryo cryopreservation, depending on the level of patient coverage
and on policy. Fertility is an additional category for most insurance
companies thatmust be selected, or thepolicy has to be open for a specified
time, depending on the insurance type. The Australian hospitals surveyed
cover the costs for fertility preservation procedures. Storage costs vary.
Recently, there have been new applications for oncofertility item numbers
(1) AMH testing before or after cancer treatment; (2) ovarian transposition;
(3) processing and handling ovarian cryopreservation, testicular
cryopreservation, and semen; and (4) psychological support during and
after fertility preservation. Outcomes are pending.
$$$$
(Continued on following page)
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The American Society for Reproductive Medicine
and ASCO recommend that psychological coun-
seling be offered before cancer treatment.12,13
Ready access to a psychologist during the fertility
preservation counseling process has been shown
to help to reduce patient anxiety as well as en-
hance communication between relevant medical
professionals because the patient’s individual
needs are more readily identified.14 Moreover, a
marked reduction in anxiety and depression is
seen in patients who receive structured cognitive
behavioral counseling.15 Specialized counseling
is associated with higher quality-of-life indications
and less regret.1 The fact that 30of40 (75%)of the
oncofertility centers surveyed provide formal psy-
chological counseling to patients with cancer is
encouraging.
The ability to have one’s own biologic children is a
priority topatientswithcancer, and fertility loss can
be a source of significant distress.15 ASCO pub-
lished updated guidelines in 2013 that recom-
mend that oncologistsdiscuss fertility preservation
options with patients at risk for infertility as a result
of their treatment.8 Resistance among oncologists
to discuss fertility issuesmaybe due to physicians’
desire to treat cancersasquicklyaspossible and to
prioritize discussions about cancer therapy and
management. Studies have found that when the
prognosis is poor, oncologists are less likely to refer
patients to reproductive endocrinology specialists
or to bring up fertility discussions at all.8 Physician
reluctance to discuss fertility could also bedue to a
lack of awareness of oncofertility developments,
a lack of time, or a lack of site-specific guidelines,
especially with regard to treating pediatric
patients.8,16,17 Global stridesmust still bemade
to educate oncologists about oncofertility, the
fertility preservation options available to pa-
tients, and the importance of discussing fertility
with patients at the time of diagnosis.
To our knowledge, the costs and legal restrictions
to care in the field of oncofertility have never been
systematically identified or analyzed by region or
center. This information should be readily acces-
sible to patients and providers. Specifically, egg,
sperm, and embryo donation often may not be
Table 2. Regional Estimates of the Potential Out-of-Pocket Financial Burden of Fertility Preservation Procedures for Patients With Cancer (Continued)
Continent and Country Coverage of Fertility Preservation Procedures Rank of Cost to Patient
South America
Argentina Insurance covers the cost of most fertility preservation procedures, especially
for patients with cancer.
0-$
Brazil No coverage. The approximate cost of egg cryopreservation is 3,500-4,500
USD (with medication), embryo cryopreservation is approximately
4,500- 5,500 USD (with medication), ovarian tissue cryopreservation
is approximately 4,000 USD (including the surgery), and sperm
cryopreservation is approximately 400USD. Costs vary by region as a result
of tax disparities between various states and populations with distant
purchasing power. No coverage exists for tissue storage as well. Cost for
cryopreserved tissue storage is approximately 150 USD, with an annual
maintenance cost of approximately 250 USD.
$$$$
Chile Costs are partially covered. Insurance and public hospitalsmay cover some of
the costs of ovarian tissue collection. Ovarian tissue cryopreservation is
covered by university research grants. Sperm storage is fully paid for by
public and private insurance. Oocyte and embryo banking are not covered
by insurance or public assistance. The approximate cost of egg
cryopreservation is 4,000 USD (with medication), whereas embryo
cryopreservation is approximately 5,000 USD (with medication).
$$$$
Peru No insurance coverage. Fertility preservation procedures for patients with
cancerare just starting tobeoffered, so at thispoint, patientsare responsible
for all costs. Starting fee is approximately 1,500 USD for ovarian
cryopreservation and an additional 600 USD for ex vivo IVM if performed in
parallel (both fees do not include the expenses related to surgical
procedures to remove the ovary). Cost is approximately 3,000 USD for
a regular IVM procedure (including embryo cryopreservation).
$$$
NOTE. The rank of cost to patient scale is as follows: 0, no out-of-pocket costs to patients; $, very little costs to patients (eg, only storage or small costs formedications; range, 0-200
USD); $$, some costs to patients (range, 200-1,000 USD); $$$, great costs to patients (range, 1,000-3,000 USD); $$$$, no coverage or steep costs that patients are generally
responsible for (range, > 3,000 USD).
Abbreviations: AMH,anti-Mu¨llerianhormone;ART, assisted reproductive technology; ICSI, intracytoplasmic sperm injection; IVF, in vitro fertilization; IVM, in vitromaturation;PCO,
polycysticovarian syndrome; USD, US dollars.
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accessible and for this reason, not discussed as a
future option at the initial consultation because of
financial, cultural, and legal restraints. Specifi-
cally, the respondents from the Banco de Seˆmen
do Rio de Janeiro in Brazil stated that the lack of
compensation for sperm donors is a huge barrier
to providing this service to their patients. Cultural
customs play a significant role in the regulation
of third-party assisted reproductive technolo-
gies, which are explicitly observed in two surveyed
countries, Egypt and Tunisia. Both countries out-
law egg, sperm, and embryo donation.18
Lackof insurancecoverageposesagreat barrier to
patient access to oncofertility care.19,20 Of note,
insurance in Tunisia only covers costs of fertility
preservation procedures in cases where a couple
has demonstrated infertility. Infertility is difficult, if
not impossible, for pediatric and unmarried pa-
tients to prove, which imposes an undue finan-
cial challenge to this proportion of oncofertility
patients. Costs for fertility preservation proce-
dures in Tunisia remain lower than at other sites,
but only approximately 50% of patients follow
through with procedures because of the high cost
of gonadotropins.
In the United States, a paradox exists about in-
surance coverage of fertility preservation proce-
dures. Insurance generally covers the costs of
iatrogenic conditions that result from cancer
treatment, such as mastectomy and wigs for alo-
pecia.21However,despite the fact that infertility asa
result of cancer is iatrogenic, fertility preservation
procedures are considered an exception and often
arenot coveredbygovernment-subsidizednational
insurance or private companies.21 Insurance com-
panies require burden of proof for infertility; there-
fore,couplesmustdemonstrate1yearofunsuccessful
attempts to conceive before they receive the diag-
nosis of infertility. This policy is unacceptable be-
cause fertility preservation addresses the potential
future infertility of currently fertile individuals.21
Changes in policy are needed to ensure that all
iatrogenic conditions after cancer treatment are
covered by national health insurance systems, and
hopefully, private insurers will follow suit.
As of 2016, 31 countries are part of the surveyed
OC Global Partners Network. This list is not ex-
haustive, and oncofertility practicing organiza-
tions in other countries were not included in this
analysis. That said, this study represents a first
attempt to quantify services in this emerging disci-
pline. Fertilitymanagement is complex andmust
take into account culturally sensitive attitudes
within each region of the world, and reanalysis of
the services provided is important as this field
expands.
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APPENDIX
Table A1. RespondentOrganizationsListedbyContinent andCountry (OrganizedAccording to theUnitedNationsStatistics
Division Geographical Region Groupings)
Continent and Country Respondent Organization
Africa
Egypt National Research Centre of Egypt (NRC)
Tunisia ART Center, Aziza Othmana Hospital of Tunis
Asia
China The First Affiliated Hospital of Nanjing Medical University
India Centre for Fertility Preservation,KasturbaMedical College,Manipal
University
Iran (Islamic Republic of) Royan Institute
Japan Gifu University Graduate School of Medicine
Japan Society for Fertility Preservation (JSFP), St Marianna
University School of Medicine
Korea (Republic of) TheKoreanSociety for Fertility Preservation (KSFP), SeoulNational
University Bundang Hospital
Turkey Onkofertilite Turkiye
Europe
Austria Medical University of Innsbruck, Austria
Belgium Centrum voor Reproductieve Geneeskunde (CRG)
Denmark University Hospital of Copenhagen, Laboratory of Reproductive
Biology
France Hoˆpital Jean-Verdier
Germany Medical Faculty of Cologne, Uniklinik Ko¨ln
Poland Oncofertility Poland, Jagiellonian University Medical College
Portugal Centro de Preservaç~ao da Fertilidade
Netherlands Radboud University Medical Center (Radboudumc)
Russian Federation Biologic Cryobank
Spain Instituto de Investigacio´n Sanitaria La Fe, Hospital Universitario y
Polite´cnico La Fe
United Kingdom of Great Britain and
Northern Ireland
Edinburgh Fertility & Reproductive Endocrine Centre
North America
Canada McGill University Health Centre Reproductive Centre
Mexico Instituto Nacional de Ciencias Me´dicas y Nutricio´n Salvador
Zubiran
Panama IVF Centro de Reproduccio´n (IVFPANAMA)
United States Oncofertility Consortium, Northwestern Medicine
Oceania
Australia Royal Children’s Hospital Melbourne Australia
Sydney Children’s Hospital and Prince of Wales Hospital Sydney
Australia
(Continued on following page)
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Table A1. Respondent Organizations Listed by Continent and Country (Organized According to the United Nations
Statistics Division Geographical Region Groupings) (Continued)
Continent and Country Respondent Organization
South America
Argentina Pregna Medicina Reproductiva
Brazil Banco de Seˆmen do Rio de Janeiro
Clı´nica IVI S~ao Paulo - Brasil
Fertilitat Centro de Medicina Reprodutiva
Fertility Preservation Research Group of the Federal University of
S~ao Jo~ao Del Rei
Fertipraxis Centro de Reproduç~ao Humana
GENESIS - Centro de Assisteˆncia em Reproduç~ao Humana
Hemoce - Centro de Hematologia e Hemoterapia do Ceara´
Huntington Medicina Reprodutiva
Pro´-Criar Medicina Reprodutiva
Universidade Federal de Minas Gerais Human Reproduction
Laboratory
Vida Centro de Fertilidade
Chile Centro de Reproduccio´n Humana - Universidad de Valparaı´so
(CRH-ultraviolet)
Peru Centro de Estudios e Investigaciones en Biologı´a y Medicina
Reproductiva - BIOMER
NOTE. Composition of macro geographical (continental) regions, geographical subregions, and selected economic and other groupings
(United Nations Statistics Division, 2016. http://unstats.un.org/unsd/methods/m49/m49regin.htm).
Table A2. Survey Questions Asked of Oncofertility ConsortiumGlobal Partners NetworkMembers and Other Experts in the
Field and the Corresponding Number of Respondent Organizations
Survey Question No. of Respondents
Is there a patient referral system at your center? If yes, does your center have a nurse
navigator, social worker, or specific oncofertility patient navigator? Please describe.
40
Do you provide psychological support to patients? If yes, please describe. 40
Does your center have a registry? 40
Which fertility preservationmethods does your center offer to patients? See options given
in Figure 1
40
Which methods are used most often? 40
Are there any services that are not offered due to cultural/religious boundaries or other
restrictions? Please explain.
23
On average, how long does the process take from diagnosis to consult? 37
On average, how long does the process take from consult to fertility preservation? 37
Onaverage,how longdoes theprocess take fromfertilitypreservation tocancer treatment? 36
Please describe in detail the referral process at your center. Are the referral rates known?
If so, what are the referral rates?
30
Does insurance cover the costs of fertility preservation procedures? If no, how do patients
pay for fertility preservation services and about howmuch do services cost? Do you feel
that these costs may deter patients from seeking fertility preservation procedures?
Please be specific.
37
What barriers or challenges do you face at your center, if any? 37
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Table A3. Frequency and Percentage of Yes/No Responses
Survey Question Yes No Total Yes, % No, %
Is there a patient referral system at your
center?
30 10 40 75 25
Does your center have a nurse navigator,
social worker, or specific oncofertility
patient navigator?
9 25 34 27 73
Do you provide psychological support to
patients?
30 10 40 75 25
Does your center have a registry? 35 5 40 87 13
Does insurance cover the costs of fertility
preservation procedures?
11 26 37 30 70
Are there any services that are not offered
due to cultural/religious boundaries or
other restrictions?
14 9 23 61 39
Table A4. Average Referral Times Indicated by Respondent Organizations
Type of Referral Time Frequency %
Time from cancer diagnosis to fertility
preservation consultation.
1-2 days 14 35
3-5 days 9 23
1 week 8 20
2 weeks 4 10
. 3 weeks 2 5
No response 3 7
Time from fertility preservation consultation
to fertility preservation.
1-2 days 9 23
3-5 days 9 23
1 week 7 17
2 weeks 8 20
. 3 weeks 4 10
No response 3 7
Time from fertility preservation to cancer
treatment.
1-2 days 8 20
3-5 days 11 27
1 week 8 20
2 weeks 5 13
. 3 weeks 4 10
No response 4 10
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